Update on legal action against MGI Australia

27 February 2026

Oxford Nanopore Technologies plc 

("Oxford Nanopore" or the "Company") 

Update on legal action against MGI Australia Pty Ltd., in the Federal Court of Australia 

Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore based molecular sensing, today noted that in the Australian patent proceedings against MGI Australia Pty Ltd. et al. ("MGI"), MGI has conceded that its "Cyclone SEQ WT02" infringes four of Oxford Nanopore's Australian patents.  

Justice Jackman confirmed at a recent case management hearing that liability for infringement is not in dispute. A trial has been set for 2027 at which MGI's remaining defences will be adjudicated. Consideration of additional or enhanced damages will take place after the trial.

Separately, in the UK, Oxford Nanopore has issued proceedings in the High Court alleging trade secrets infringement, breach of confidence and breach of contract against multiple MGI/ BGI entities.

In both instances, Oxford Nanopore initiated legal proceedings to protect the intellectual property ("IP") that underpins its sensing platform, supported by patents granted in Australia and in many other jurisdictions. The Company continues to invest in innovation and is committed to safeguarding this IP as a core driver of long-term value creation for customers and partners worldwide.

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:   [email protected] 

Media:       [email protected] 

Teneo Australia (communications adviser to the Company)

Scott McFarlane:  +61 493 119 547

Australian media: [email protected] 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. 

For more information please visit: www.nanoporetech.com